Teva Pharmaceutical Industries (TEVA) Tax Provisions (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Tax Provisions across 10 years of filings, most recently posting $67.0 million for Q1 2026.

• Quarterly Tax Provisions fell 9.46% year-over-year to $67.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$187.0 million (down 123.35% YoY) and the FY2025 annual result came in at -$180.0 million, down 126.63% from the prior year.
• Tax Provisions grew to $67.0 million in Q1 2026, from -$390.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $630.0 million in Q2 2024 and troughed at -$900.0 million in Q2 2022.
• A 5-year average of -$5.1 million and a median of $28.0 million in 2024 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2024 — Tax Provisions soared 4037.5% — and 2025, when it sank 1492.86%.
• Tracing TEVA's Tax Provisions over 5 years: stood at $149.0 million in 2022, then sank by 72.48% to $41.0 million in 2023, then sank by 31.71% to $28.0 million in 2024, then plunged by 1492.86% to -$390.0 million in 2025, then soared by 117.18% to $67.0 million in 2026.
• Business Quant data shows TEVA's Tax Provisions at $67.0 million in Q1 2026, -$390.0 million in Q4 2025, and $214.0 million in Q3 2025.